Contineum Therapeutics Completes Enrollment In Phase 2 PIPE-307 VISTA Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis; The Last Patient Is Expected To Complete The Trial In Q3 2025
Contineum Therapeutics Completes Enrollment In Phase 2 PIPE-307 VISTA Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis; The Last Patient Is Expected To Complete The Trial In Q3 2025
- Targeted enrollment of 168 RRMS patients achieved in December 2024
- The last patient is expected to complete the trial in the third quarter of 2025
- 計劃在2024年12月招募168名RRMS患者
- 最後一名患者預計將在2025年第三季度完成試驗
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial. PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting multiple sclerosis (RRMS).
Contineum Therapeutics, Inc. (納斯達克:CTNM)（Contineum或公司）是一家臨牀階段的生物製藥公司，致力於爲神經科學、炎症和免疫學（NI& I）適應症開發差異化療法。今天宣佈已完成其第二階段PIPE-307 VISTA試驗中168名患者的目標招募。PIPE-307是一種潛在的首創M1受體拮抗劑，正在開發用於複發性緩解型多發性硬化症（RRMS）患者。
The Phase 2, randomized, double-blind, placebo-controlled, multi-center, proof-of-concept trial of PIPE-307 will assess safety and efficacy in RRMS patients. The trial is designed to measure multiple clinical and imaging endpoints sensitive to changes in remyelination in RRMS. Contineum anticipates that the last patient will complete the PIPE-307 VISTA trial in the third quarter of 2025. More information on this trial can be found at (NCT06083753).
PIPE-307的第二階段、隨機、雙盲、安慰劑對照、多中心的概念驗證試驗將評估RRMS患者的安全性和療效。該試驗旨在測量多個對RRMS再髓鞘化變化敏感的臨牀和影像學終點。Contineum預計最後一名患者將在2025年第三季度完成PIPE-307 VISTA試驗。關於此試驗的更多信息可以在（NCT06083753）找到。
